Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Deutsche Bank AG (DB) vs Pfizer Inc (PFE) Price & Performance

Deutsche Bank AGTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Deutsche Bank AG vs Pfizer Inc — how do they compare? Deutsche Bank AG trades at $38.26 (market cap $72.15B), while Pfizer Inc trades at $26.58 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 2.1× Deutsche Bank AG's market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.

DBPFE
Market Cap
$72.15B$154.18B
Sector
FinancialsHealth
52-Week High
$40.33$28.56
52-Week Low
$28.37$23.60
Dividend Yield
3.04%6.36%
Volume
29,869,932
Enterprise Value
$205.67B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Deutsche Bank AG

Deutsche Bank (DB) trades at $38.06, up 1.14% with a bullish technical outlook supported by moving averages. The bank shows strong fundamentals with Q2 2026 revenue growth and a 10.02 P/E ratio trading below book value at 0.79. Recent developments include being named China's renminbi clearing bank and announcing a $500 million buyback. Net income margin improved to 22.04% in 2026, though Q2 earnings missed expectations.

DB presents a mixed investment case with attractive valuation metrics and strategic positioning in European banking, but faces execution risks from recent earnings miss and ongoing tax investigations. The stock trades at a discount to peers with moderate analyst support (21% buy rating) despite strong operational cash flow of $47.06 billion in 2025.

Pfizer Inc

Pfizer (PFE) trades at $26.74, up 2.06% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. Recent quarters show consistent earnings beats, though revenue has moderated from pandemic peaks. The company maintains a strong cash position of $20.48 billion (2024) and a dividend yield supported by a $0.43 per share payout. Key developments include a focus on obesity and oncology pipelines, with several catalysts expected in 2026.

The outlook balances a stable dividend and pipeline potential against post-COVID revenue normalization and patent cliff risks. Near-term upside exists if pipeline catalysts materialize, but investors face headwinds from competitive pressures and projected net income margin compression to 6.8% in 2026. The stock's valuation at a P/E of 35.21 appears elevated relative to earnings growth, warranting caution despite technical strength.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Deutsche Bank AG

In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.

Read more on DB

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE